Skip to main content

Table 1 Baseline clinical characteristics of study subjects

From: Efficacy of a novel hemostatic adhesive powder in patients with upper gastrointestinal tumor bleeding

Variables

Total enrolled patients (n = 41)

UI-EWD monotherapy (n = 23)

Age (year)§

74 (39–88)

76 (39–88)

Gender (Male), n (%)

31 (75.6)

32 (74.4)

The tumor pathology, n (%)

  

Adenocarcinoma

33 (80.5)

17 (73.9)

Squamous carcinoma

2 (4.9)

0 (0.0)

GIST

5 (12.2)

4 (17.4)

Lymphoma

1 (2.4)

2 (8.7)

Tumor stage, n (%)

  

1

3 (7.3)

2 (7.0)

2

2 (4.9)

0 (9.3)

3

6 (14.6)

3 (16.3)

4

30 (73.2)

18 (67.4)

ASA score, (%)

  

1

2 (4.9)

1 (4.3)

2

7 (17.1)

4 (17.4)

3

18 (43.9)

10 (43.5)

4

13 (31.7)

7 (30.4)

5

1 (2.4)

1 (4.3)

Comorbidity, n (%)

  

HTN

18 (43.9)

12 (47.8)

DM

12 (29.3)

5 (21.7)

Cardiovascular

13 (31.7)

7 (30.4)

CKD

4 (9.8)

2 (8.7)

Systolic blood pressure (mmHg)§

108 (74–162)

108 (74–139)

Diastolic blood pressure (mmHg)§

59 (30–96)

59 (30–91)

Heart rate (per min)§

92 (51–177)

84 (51–177)

Hb (g/dL)§

6.7 (3.7–14.0)

6.7 (3.7–14.0)

Follow up duration (day) §

107 (7–956)

57 (7–607)

  1. ASA, American society of anesthesiologist; CKD, chronic kidney disease; DM, diabetes mellitus; GIST, gastrointestinal stromal tumor; Hb, hemoglobin; HTN, hypertension
  2. §, median (range)